Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 pemafibrate (K-808) in primary biliary cholangitis with inadequate response to UDCA/OCA
jRCT2071230106Phase 2Active, not recruiting
- Sponsor
- Kowa Company, Ltd.
- Start
- Jan 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of pemafibrate in primary biliary cholangitis (PBC) (4 arms), sponsored by Kowa Company, Ltd. Primary endpoint: Percent change from baseline in serum ALP after 12 weeks of treatment. Started Jan 2024; status: active, not recruiting.
02
Drugs
pemafibrate
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on jRCT2071230106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230106.